medRxiv · 2021 · 11 citations · 28 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyAdult ImmunizationAdverse Events Following ImmunizationInactivated VaccinesVaccinationVaccine ReactogenicityVaccine SafetyAdenoviral Vaccine VectorsCoronavirus VaccinesInterferon Gamma ResponseInterferon-gamma ResponsesNeutralizing Antibody ResponsesSerious Adverse EventsVectored VaccinesViral Vector Immunogenicity
Abstract In light of intermittent supply shortages of individual vaccines and evidence of rare but serious adverse events after vaccination, heterologous regimens for COVID-19 vaccines have gained significant interest. This study aims to assess the reactogenicity and immunogenicity of the heterologous adenoviral vector vaccine regimen (ChAdOx1-S, AstraZeneca; hereafter referred to as AZ) and the inactivated vaccine regimen (CoronaVac; hereafter referred to as CV) regimen in healthy Thai adults immunized between June and September 2021. Our study showed that adverse events following homologous CV-CV and AZ-AZ, and heterologous CV-AZ and AZ-CV combinations, were mild and well tolerated overall. Receptor-binding domain (RBD)-specific antibody responses and neutralizing activities against wild-type and variants of concern after two-dose vaccination were higher in the heterologous CV-AZ and homologous AZ-AZ groups compared to the CV-CV and AZ-CV groups. Conversely, the spike-specific IgA response was detected only in the CV-AZ group after two doses of vaccination. The total interferon gamma response was detected in both the CV-AZ and AZ-CV groups after the two-dose vaccination. Given the shorter completion time of two doses, heterologous CoronaVac followed by ChAdOx1-S can be considered as an alternative regimen to homologous efficacy-proven ChAdOx1-S in countries with circulating variants. Additional studies on the efficacy and durability of immune responses induced by heterologous vaccine regimens are warranted.
28
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Uğur Şahin, Alexander Muik, Evelyna Derhovanessian et al. · Nature · 2020 · 2K citations · Full text
Development of an inactivated vaccine candidate for SARS-CoV-2
Qiang Gao, Linlin Bao, Haiyan Mao et al. · Science · 2020 · 1.5K citations · Full text
Fengcai Zhu, Yu-Hua Li, Xu-Hua Guan et al. · The Lancet · 2020 · 1.5K citations · Full text
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Shuo Feng, Daniel J. Phillips, Thomas White et al. · Nature Medicine · 2021 · 1.2K citations · Full text
IgA dominates the early neutralizing antibody response to SARS-CoV-2
Delphine Sterlin, Alexis Mathian, Makoto Miyara et al. · Science Translational Medicine · 2020 · 1.1K citations · Full text